Correlation of the Tight Junction-like Distribution of Claudin-1 to the Cellular Tropism of Hepatitis C Virus

Wei Yang, Chao Qiu, Nabanita Biswas, Jing Jin, Simon C. Watkins, Ronald C. Montelaro, Carolyn B. Coyne, Tianyi Wang

Journal of Biological Chemistry · 2008 · 108 citations · 39 references

DOIFull text

Open access

Concepts

Abstract

Claudin-1 (CLDN1), a tight junction (TJ) protein, has recently been identified as an entry co-receptor for hepatitis C virus (HCV). Ectopic expression of CLDN1 rendered several non-hepatic cell lines permissive to HCV infection. However, little is known about the mechanism by which CLDN1 mediates HCV entry. It is believed that an additional entry receptor(s) is required because ectopic expression of CLDN1 in both HeLa and NIH3T3 cells failed to confer susceptibility to viral infection. Here we found that CLDN1 was co-immunoprecipitated with both HCV envelope proteins when expressed in 293T cells. Results from biomolecular fluorescence complementation assay showed that overexpressed CLDN1 also formed complexes with CD81 and low density lipoprotein receptor. Subsequent imaging analysis revealed that CLDN1 was highly enriched at sites of cell-cell contact in permissive cell lines, co-localizing with the TJ marker, ZO-1. However, in both HeLa and NIH3T3 cells the ectopically expressed CLDN1 appeared to reside predominantly in intracellular vesicles. The CLDN1-CD81 complex formed in HeLa cells was also exclusively distributed intracellularly, co-localizing with EEA1, an early endosomal marker. Correspondingly, transepithelial electric resistance, obtained from the naturally susceptible human liver cell line, Huh7, was much higher than that of the HeLa-CLDN1 cell line, suggesting that Huh7 is likely to form functional tight junctions. Finally, the disruption of TJ-enriched CLDN1 by tumor necrosis factor-α treatment markedly reduced the susceptibility of Huh7.5.1 cells to HCV infection. Our results suggest that the specific localization pattern of CLDN1 may be crucial in the regulation of HCV cellular tropism. Claudin-1 (CLDN1), a tight junction (TJ) protein, has recently been identified as an entry co-receptor for hepatitis C virus (HCV). Ectopic expression of CLDN1 rendered several non-hepatic cell lines permissive to HCV infection. However, little is known about the mechanism by which CLDN1 mediates HCV entry. It is believed that an additional entry receptor(s) is required because ectopic expression of CLDN1 in both HeLa and NIH3T3 cells failed to confer susceptibility to viral infection. Here we found that CLDN1 was co-immunoprecipitated with both HCV envelope proteins when expressed in 293T cells. Results from biomolecular fluorescence complementation assay showed that overexpressed CLDN1 also formed complexes with CD81 and low density lipoprotein receptor. Subsequent imaging analysis revealed that CLDN1 was highly enriched at sites of cell-cell contact in permissive cell lines, co-localizing with the TJ marker, ZO-1. However, in both HeLa and NIH3T3 cells the ectopically expressed CLDN1 appeared to reside predominantly in intracellular vesicles. The CLDN1-CD81 complex formed in HeLa cells was also exclusively distributed intracellularly, co-localizing with EEA1, an early endosomal marker. Correspondingly, transepithelial electric resistance, obtained from the naturally susceptible human liver cell line, Huh7, was much higher than that of the HeLa-CLDN1 cell line, suggesting that Huh7 is likely to form functional tight junctions. Finally, the disruption of TJ-enriched CLDN1 by tumor necrosis factor-α treatment markedly reduced the susceptibility of Huh7.5.1 cells to HCV infection. Our results suggest that the specific localization pattern of CLDN1 may be crucial in the regulation of HCV cellular tropism. Hepatitis C virus (HCV), 3The abbreviations used are:HCVhepatitis C virusHCVppHIV particles pseudotyped with HCV envelope proteinsVSVppHIV particles pseudotyped with vesicular stomatitis virus envelope protein GHCVcccell culture-grown HCVCLDN1Claudin-1BiFCbiomolecular fluorescence complementation assayTNFtumor necrosis factorPBSphosphate-buffered salineGFPgreen fluorescent proteinIFNinterferonTJtight junctionFITCfluorescein isothiocyanateTERtransepithelial electric resistanceLDLRlow density lipoprotein receptor. a major human pathogen, specifically infects hepatocytes. In nature, the virus may exist in several forms: enveloped lipoprotein-free virus, enveloped lipoprotein-associated virus, non-enveloped lipoprotein-free virus, and non-enveloped lipoprotein-associated virus (1Diedrich G. FEBS J. 2006; 273: 3871-3885Crossref PubMed Scopus (28) Google Scholar). While the nature of these different forms remains elusive, they may infect cells via different means (1Diedrich G. FEBS J. 2006; 273: 3871-3885Crossref PubMed Scopus (28) Google Scholar). Importantly, pseudoviral particles that consist of an HIV core and HCV E1 and E2 (i.e. HCVpp) have been found to strictly infect human hepatocytes and a few hepatoma-derived cell lines (2Bartosch B. Dubuisson J. Cosset F.L. J. Exp. Med. 2003; 197: 633-642Crossref PubMed Scopus (959) Google Scholar, 3Cormier E.G. Tsamis F. Kajumo F. Durso R.J. Gardner J.P. Dragic T. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 7270-7274Crossref PubMed Scopus (248) Google Scholar, 4Hsu M. Zhang J. Flint M. Logvinoff C. Cheng-Mayer C. Rice C.M. McKeating J.A. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 7271-7276Crossref PubMed Scopus (695) Google Scholar). HCVpp most likely resembles enveloped lipoprotein-free viruses whose entry is dependent upon two of the HCV envelope proteins, E1 and E2 (5Cocquerel L. Meunier J.C. Pillez A. Wychowski C. Dubuisson J. J. Virol. 1998; 72: 2183-2191Crossref PubMed Google Scholar, 6Cocquerel L. Duvet S. Meunier J.C. Pillez A. Cacan R. Wychowski C. Dubuisson J. J. Virol. 1999; 73: 2641-2649Crossref PubMed Google Scholar, 7Cocquerel L. Wychowski C. Minner F. Penin F. Dubuisson J. J. Virol. 2000; 74: 3623-3633Crossref PubMed Scopus (144) Google Scholar, 8Cocquerel L. Voisset C. Dubuisson J. J. Gen. Virol. 2006; 87: 1075-1084Crossref PubMed Scopus (161) Google Scholar, 9Bartosch B. Cosset F.L. Virology. 2006; 348: 1-12Crossref PubMed Scopus (135) Google Scholar). A plethora of evidence that has been accumulated from studies employing HCVpp has allowed for a proposed model of HCV entry: HCV attaches to hepatocytes via specific receptor(s) followed by clathrin-dependent internalization (endocytosis) (10Codran A. Royer C. Jaeck D. Bastien-Valle M. Baumert T.F. Kieny M.P. Pereira C.A. Martin J.P. J. Gen. Virol. 2006; 87: 2583-2593Crossref PubMed Scopus (65) Google Scholar, 11Blanchard E. Belouzard S. Goueslain L. Wakita T. Dubuisson J. Wychowski C. Rouille Y. J. Virol. 2006; 80: 6964-6972Crossref PubMed Scopus (442) Google Scholar). Internalized virions then traffic to early endosomes where the virion envelope proteins undergo conformational changes and then fuse with the cellular membrane for viral entry (4Hsu M. Zhang J. Flint M. Logvinoff C. Cheng-Mayer C. Rice C.M. McKeating J.A. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 7271-7276Crossref PubMed Scopus (695) Google Scholar, 12Meertens L. Bertaux C. Dragic T. J. Virol. 2006; 80: 11571-11578Crossref PubMed Scopus (234) Google Scholar). In numerous attempts to identify an HCV entry receptor(s), both human tetraspanin CD81 and the human scavenger receptor, SR-BI, were isolated in screens based on sE2 binding (9Bartosch B. Cosset F.L. Virology. 2006; 348: 1-12Crossref PubMed Scopus (135) Google Scholar, 13Pileri P. Uematsu Y. Campagnoli S. Galli G. Falugi F. Petracca R. Weiner A.J. Houghton M. Rosa D. Grandi G. Abrignani S. Science. 1998; 282: 938-941Crossref PubMed Scopus (1809) Google Scholar, 14Scarselli E. Ansuini H. Cerino R. Roccasecca R.M. Acali S. Filocamo G. Traboni C. Nicosia A. Cortese R. Vitelli A. EMBO J. 2002; 21: 5017-5025Crossref PubMed Scopus (965) Google Scholar). Intensive studies using HCVpp and the recently developed cell culture-grown HCV system (HCVcc) have now firmly established the necessary roles of CD81 and SR-BI in HCV entry (2Bartosch B. Dubuisson J. Cosset F.L. J. Exp. Med. 2003; 197: 633-642Crossref PubMed Scopus (959) Google Scholar, 3Cormier E.G. Tsamis F. Kajumo F. Durso R.J. Gardner J.P. Dragic T. Proc. Natl. Acad. Sci. U. S. A. 2004; 101: 7270-7274Crossref PubMed Scopus (248) Google Scholar, 15Petracca R. Falugi F. Galli G. Norais N. Rosa D. Campagnoli S. Burgio V. Di Stasio E. Giardina B. Houghton M. Abrignani S. Grandi G. J. Virol. 2000; 74: 4824-4830Crossref PubMed Scopus (199) Google Scholar, 16Zhang J. Randall G. Higginbottom A. Monk P. Rice C.M. McKeating J.A. J. Virol. 2004; 78: 1448-1455Crossref PubMed Scopus (315) Google Scholar, 17Lindenbach B.D. Evans M.J. Syder A.J. Wolk B. Tellinghuisen T.L. Liu C.C. Maruyama T. Hynes R.O. Burton D.R. McKeating J.A. Rice C.M. Science. 2005; 309: 623-626Crossref PubMed Scopus (1965) Google Scholar, 18Kato T. Date T. Miyamoto M. Zhao Z. Mizokami M. Wakita T. J. Virol. 2005; 79: 592-596Crossref PubMed Scopus (101) Google Scholar). hepatitis C virus HIV particles pseudotyped with HCV envelope proteins HIV particles pseudotyped with vesicular stomatitis virus envelope protein G cell culture-grown HCV Claudin-1 biomolecular fluorescence complementation assay tumor necrosis factor phosphate-buffered saline green fluorescent protein interferon tight junction fluorescein isothiocyanate transepithelial electric resistance low density lipoprotein receptor. Most recently, Evans et al. (19Evans M.J. von Hahn T. Tscherne D.M. Syder A.J. Panis M. Wolk B. Hatziioannou T. McKeating J.A. Bieniasz P.D. Rice C.M. Nature. 2007; 446: 801-805Crossref PubMed Scopus (1000) Google Scholar) have identified a tight junction (TJ) protein, Claudin-1 (CLDN1), as the third entry co-receptor for HCV. Like CD81, CLDN1 spans the plasma membrane four times and is a component of the tight junction barrier that restricts the free exchange of ions and aqueous molecules between cells (20Van Itallie C.M. Anderson J.M. Physiology 2004; PubMed Scopus Google Scholar, J. 2004; PubMed Scopus Google Scholar). It was that CLDN1 is required for HCV of human cell lines and was the factor to confer susceptibility to HCV when ectopically expressed in non-hepatic cell (19Evans M.J. von Hahn T. Tscherne D.M. Syder A.J. Panis M. Wolk B. Hatziioannou T. McKeating J.A. Bieniasz P.D. Rice C.M. Nature. 2007; 446: 801-805Crossref PubMed Scopus (1000) Google Scholar). the of the protein the intracellular required for HCV entry. While the of CLDN1 in HCV entry remains was to between virions and cell in a assay (19Evans M.J. von Hahn T. Tscherne D.M. Syder A.J. Panis M. Wolk B. Hatziioannou T. McKeating J.A. Bieniasz P.D. Rice C.M. Nature. 2007; 446: 801-805Crossref PubMed Scopus (1000) Google that is a component for entry. However, several cell lines to HCVpp upon the ectopic expression of It is to that an additional is required for viral entry. In an to the of CLDN1 in HCV we studies and that overexpressed CLDN1 with HCV E1 and CD81, and the low density lipoprotein then found that the of CLDN1 with the of the cells to HCVpp infection. ectopically expressed CLDN1 in lines was predominantly intracellular in permissive lines, was enriched at sites of cell-cell Huh7 cells a transepithelial electric resistance with HeLa-CLDN1 that they form functional that free CLDN1 also with the TJ marker, at cell-cell in Huh7 suggesting that these cells form Finally, tumor necrosis factor treatment the cell expression of CLDN1 in the Huh7.5.1 cell as a cells showed susceptibility to HCVpp infection. results suggest that cell CLDN1 localization may be a mechanism by which the HCV cellular is and human cell the human cell NIH3T3 cells and the human cell were from The The human cell and the human cell HeLa were both obtained the and cells were by of The human liver cell Huh7 was obtained from with the of Rice The Huh7.5.1 from a HCV cell was by A Huh7 cell was a from G. of Z. Zhang C. J. Wakita T. G. J. Virol. 2005; 79: PubMed Scopus Google Scholar). cell lines were in with and and The cell was in with and and were obtained from Dubuisson and and and and human CD81, HCV and envelope protein were the sites of the and to to of the protein, the to the C of the and CD81 were also between the sites of the for was by the between the sites of the upon E1 and E2 were by Rice HCV E1 and E2 (4Hsu M. Zhang J. Flint M. Logvinoff C. Cheng-Mayer C. Rice C.M. McKeating J.A. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 7271-7276Crossref PubMed Scopus (695) Google Scholar). of the cells were to at cells in a in of The cells were using the The was of of the and of from of the the HIV proteins and were the and and the was of the of the a the is for In HCVpp and particles pseudotyped with HCV E1 and E2 with A was also as the the of was by the of was HCVpp were and then a HIV particles be formed and in the of the protein, the of in the is an of HCVpp viral viral using an is used to the of The viral for HCVpp using the is between and HCVpp the cell lines were in a at a density of to The of HCVpp virus was in the of and of and in a were in of and then of was cells were in of and was with of assay to the assay used a and obtained from to The from a is than and cell cells were with assay with a on The was by at for in were a the proteins were a membrane The were in for and then with at The used in the was a of The was used as the for the cell were with and with were by and with and HCV virus we virus by a cell The HCV by was then used to infect a human liver cell to a J. P. G. S. T. Burton D.R. Wakita T. Proc. Natl. Acad. Sci. U. S. A. 2005; PubMed Scopus Google Scholar). was viruses were and at was to virus B.D. Evans M.J. Syder A.J. Wolk B. Tellinghuisen T.L. Liu C.C. Maruyama T. Hynes R.O. Burton D.R. McKeating J.A. Rice C.M. Science. 2005; 309: 623-626Crossref PubMed Scopus (1965) Google Scholar). the viral cells were on in at HCV was in and used to infect the cells were and cells were in of for at cells were in for the a of the HCV core protein was and the was at for a was as a the was and cells were times with of followed by an with of for at was and the cells were times with The were then on and with at a were obtained by an fluorescence of the cells were for core we then the viral as Our viral from to and cells were in were then with in times in in and in with CLDN1 and were in and with in to the were on and with were by a using and using In most the was with a developed by Liu H. 2006; PubMed Scopus Google Scholar) for were with and cells on a the of the cell density was The of was at as of was to the of Liu H. 2006; PubMed Scopus Google Scholar). cells were and for when were then by using the the of cells were in and by Huh7, and cells were on a membrane that were in of were to the and of was to the in was for using an A with cells was and the resistance from the was from the was as cells cells with specific for CD81 were on a were and using between CLDN1 and HCV CLDN1 was as an entry co-receptor for little is known about the between CLDN1 and HCV envelope proteins and and found that HCV E1 and E2 when E1 and E2 were in 293T cells from the E1 and E2 known to (5Cocquerel L. Meunier J.C. Pillez A. Wychowski C. Dubuisson J. J. Virol. 1998; 72: 2183-2191Crossref PubMed Google Scholar, A. R. Duvet S. L. Cacan R. B. M. Penin F. Dubuisson J. J. 2000; PubMed Google we expressed E1 and E2 in 293T cells and found that both E1 and the be with overexpressed HCV E2 with CLDN1 in in both and HeLa cells C and results suggest that in CLDN1 is to with both HCV which is in with CD81 and SR-BI, both of which with E2 P. Uematsu Y. Campagnoli S. Galli G. Falugi F. Petracca R. Weiner A.J. Houghton M. Rosa D. Grandi G. Abrignani S. Science. 1998; 282: 938-941Crossref PubMed Scopus (1809) Google Scholar, 14Scarselli E. Ansuini H. Cerino R. Roccasecca R.M. Acali S. Filocamo G. Traboni C. Nicosia A. Cortese R. Vitelli A. EMBO J. 2002; 21: 5017-5025Crossref PubMed Scopus (965) Google Scholar, L. C.C. Dubuisson J. S. J. Virol. 2003; PubMed Scopus Google Scholar). and HeLa cells were for these studies because of of and with the human cell It be that of these lines CLDN1 A and Ectopic expression of CLDN1 rendered HeLa cells susceptible to HCVpp and proteins used in were to be functional in of CLDN1 with CD81 and the between CLDN1 and HCV as CD81 and we a the assay In a a fluorescent protein is and the to of proteins to these fluorescence when the two fluorescent protein in than The assay has been used to of and J. T. C. J. Virol. 2007; PubMed Scopus Google Scholar). a of proteins with the and of the fluorescence protein for of the of assay the is that the be by In CLDN1 formed a complex with CD81, and with the be in the Huh7 cell CD81 complex with HCV E2 which is with a L. C.C. Dubuisson J. S. J. Virol. 2003; PubMed Scopus Google Scholar). these results the of the of we the expression of the by analysis and found that they expressed we these HCVpp entry. CD81, were to HCVpp entry 293T cells and CD81 was to cells permissive to HCVpp and be on the cell as suggesting that the of the was to CD81 HCV entry cells is a low (10Codran A. Royer C. Jaeck D. Bastien-Valle M. Baumert T.F. Kieny M.P. Pereira C.A. Martin J.P. J. Gen. Virol. 2006; 87: 2583-2593Crossref PubMed Scopus (65) Google Scholar, 12Meertens L. Bertaux C. Dragic T. J. Virol. 2006; 80: 11571-11578Crossref PubMed Scopus (234) Google Scholar). to the localization of the CLDN1-CD81 and complexes by It appeared that CLDN1-CD81 and both on plasma as as in both A and and cell lines The intracellular of the formed complex with early an early endosomal marker. in HeLa the CLDN1-CD81 complex was exclusively in the and with However, the with at of CLDN1 and to on the we that CLDN1 may be distributed different cell and the of CLDN1 may be in in the of viral entry. we the cellular of CLDN1 in cell results revealed that CLDN1 in Huh7 cells formed a the TJ protein pattern that has been in and cell lines M. T. S. J. 1998; PubMed Scopus Google Scholar, J.M. 2006; PubMed Scopus Google Scholar). In ectopically expressed is highly enriched at the sites of cell-cell contact with in the in and 293T appeared to be exclusively intracellular in HeLa and NIH3T3 cells the that the intracellular of CLDN1 in HeLa cells was to a of that to low we a HeLa-CLDN1 cell cells also CLDN1 localization predominantly intracellular with and 293T cells permissive to by HCVpp upon ectopic expression of HeLa and NIH3T3 when both CD81 and CLDN1 were expressed HeLa cells naturally CD81 and SR-BI, two of the known required for HCV entry (4Hsu M. Zhang J. Flint M. Logvinoff C. Cheng-Mayer C. Rice C.M. McKeating J.A. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 7271-7276Crossref PubMed Scopus (695) Google Scholar). However, CD81, and HeLa NIH3T3 cells to cell lines for CLDN1 expression on plasma and for expression of both CD81 and The human cell because expressed both CLDN1 at cell-cell and CD81 It also expressed SR-BI A. H. A. B. P. H. T. E. Sci. 2004; PubMed Google Scholar). be by at much with However, low is to the of the HIV core protein in cells also in an in with that in Huh7 cells The human was also permissive to HCVpp and expressed known HCV J. P. McKeating J.A. J. Virol. PubMed Scopus Google and In the HeLa-CLDN1 to of in Huh7 of CLDN1 at cell-cell in permissive cell lines is of the pattern of a Huh7 cells of functional (i.e. localization of and to the we the cells with tight junction and transepithelial electric found that CLDN1 with at cell-cell which was to the pattern in the cell which known to form expressed CLDN1 also with in and 293T cells at cell-cell contact sites in HeLa cells in NIH3T3 the of appeared to be low and a of ectopically expressed CLDN1 with was However, the of was different from was in Huh7 cells in that was on cell-cell contact sites when the transepithelial electric resistance was Huh7 cells developed a with was for cells. In the resistance obtained from a HeLa-CLDN1 cell is a of the of cells (i.e. TJ Huh7 cells the of cell of CLDN1 plasma TJ-enriched CLDN1 is required for HCV the disruption of CLDN1 localization is to HCV entry. by cells with as and have been to by the internalization of TJ proteins in cells M. M. C.A. A. J. 2005; PubMed Scopus Google Scholar). in plasma CLDN1 a the of HCVpp in these cells in a In of was by treatment The be in Huh7.5.1 cells that were with as the of the HCV core protein in cells that were with in a was to HCV protein M. A. V. V. R. J. Gen. Virol. 2003; PubMed Scopus Google is most likely to the of entry cells. that is the we cells with to treatment and found on HCV core protein expression the used cell as by and The of the TJ protein CLDN1 as a HCV co-receptor has CLDN1 with HCV is the between CLDN1 and HCV is CLDN1 in HCV The in specifically these and a of the that CLDN1 in HCV entry. between CLDN1 and HCV and is the to that overexpressed CLDN1 with both HCV has the of evidence that CLDN1 is of with HCV envelope studies required to CLDN1 contact with virions entry CLDN1 an in virus entry. In ectopically expressed CLDN1 and HCV E2 in HeLa and at the cell be by the overexpressed proteins to have a intracellular and a specific of the is required for the to and is found on an viral the system viral when viral proteins be to HCV with CLDN1 viral and that viral and The assay for the of the results be and the assay for the imaging of the of an we were to the we identified between CD81, and In a that CLDN1 with and CD81 and in membrane of cell lines 2007; PubMed Scopus Google Scholar). CLDN1 at the of viral entry as proposed (19Evans M.J. von Hahn T. Tscherne D.M. Syder A.J. Panis M. Wolk B. Hatziioannou T. McKeating J.A. Bieniasz P.D. Rice C.M. Nature. 2007; 446: 801-805Crossref PubMed Scopus (1000) Google with CD81 and may upon viral in to by both and studies of Huh7 the most about HCV entry is the cells membrane localization of CLDN1 for is of that CLDN1 to in hepatocytes. A of cells showed that the disruption of TJ by HCV viral that CLDN1 may be for viral entry J. P. McKeating J.A. J. Virol. PubMed Scopus Google Scholar). Our at the that CLDN1 is required for HCV entry. permissive cell lines that we CLDN1 to reside predominantly in TJ and is with ZO-1. In Huh7 cells form functional as by and transepithelial electric resistance is that hepatocytes highly N. J. PubMed Scopus Google a that is dependent upon the of tight between cells. to that the cellular of the used Huh7 cell and highly permissive to and HCVpp to be However, cells form M. T. S. J. 1998; PubMed Scopus Google Scholar). have now that CLDN1 in permissive cell lines is highly enriched at cell-cell that In CLDN1 with CD81 and on plasma in permissive cells and the disruption of CLDN1 viral entry. the mechanism by which HCV CLDN1 remains is to that the virus may a to that by which via binding on the and to the complex P. J. M.J. 2002; PubMed Scopus Google Scholar, J.M. J.A. G. A. Science. PubMed Scopus Google Scholar). studies be required to the by HCV to and the of CLDN1 in HCV entry. of CLDN1 in HCV cells from the a disruption of TJ the specific internalization of a membrane component with to J.M. 2006; PubMed Scopus Google Scholar, B. R. 2007; PubMed Scopus Google Scholar). is required for a in virus entry. entry of enveloped HCV particles has been to on clathrin-dependent E. Belouzard S. Goueslain L. Wakita T. Dubuisson J. Wychowski C. Rouille Y. J. Virol. 2006; 80: 6964-6972Crossref PubMed Scopus (442) Google Scholar, 12Meertens L. Bertaux C. Dragic T. J. Virol. 2006; 80: 11571-11578Crossref PubMed Scopus (234) Google Scholar). However, CD81 SR-BI, two of the known required HCV entry is the CLDN1 and TJ proteins have been to be between endosomes and TJ via a clathrin-dependent mechanism A. C.A. 2004; PubMed Scopus Google Scholar). of cells with by the internalization of several TJ proteins, junction and CLDN1 M. M. C.A. A. J. 2005; PubMed Scopus Google Scholar). was identified as the for and by binding to the of J. Y. N. M. S. FEBS 2000; PubMed Scopus Google Scholar). It is that binding of the virions to CLDN1 may CLDN1 viral entry. with CLDN1 forms a complex with CD81 on the plasma membrane as as in the of Huh7, and cell The intracellular CLDN1-CD81 complex with EEA1, an early endosomal marker. HCV attaches to cells via CD81 cellular receptor(s) followed by the of the virus to It may then early endosomes where a low the to the of virus the CLDN1 may as a membrane upon which cellular HCV entry to form an entry undergo that from that HCV entry is of the to which proteins (19Evans M.J. von Hahn T. Tscherne D.M. Syder A.J. Panis M. Wolk B. Hatziioannou T. McKeating J.A. Bieniasz P.D. Rice C.M. Nature. 2007; 446: 801-805Crossref PubMed Scopus (1000) Google Scholar). The of CLDN1 with these proteins likely to be for CLDN1 with CD81 and on the cell and is of binding to both HCV E1 and E2 proteins, viral of CLDN1 mediates HCV we have identified a mechanism by which cellular of HCV is cell may CLDN1 and susceptibility to HCV infection. In HeLa and NIH3T3 ectopically expressed CLDN1 is in early to the of CLDN1 to the cell to be on the In is because CLDN1 have been P. Y. C. J. J. 2005; PubMed Scopus Google Scholar, M. J. L. D. PubMed Scopus Google Scholar). the was to the of CLDN1 in Y. N. S. H. S. S. T. 2003; PubMed Scopus Google Scholar). is distributed in in cells with the TJ marker, in cells A. G. M. R. A. D. J. PubMed Scopus Google that the localization of is also tight CLDN1 and expression may viral entry. The that non-hepatic cell lines and by HCVpp that cell that CLDN1 on with may be permissive to HCV as It was proposed that HeLa cells were to HCV because they the expression of an co-receptor (19Evans M.J. von Hahn T. Tscherne D.M. Syder A.J. Panis M. Wolk B. Hatziioannou T. McKeating J.A. Bieniasz P.D. Rice C.M. Nature. 2007; 446: 801-805Crossref PubMed Scopus (1000) Google Scholar). In suggest that the of CLDN1 cell may these cells to infection. that CLDN1 likely that may C. F. G. F. J. H. and T. Wakita for cell lines, and also to G. and J. for with to and for of the with

References

39